Patents Assigned to Neuropill, Inc.
  • Methods for treating conditions caused by higher-than-normal dopaminergic activity in basal ganglia
    Patent number: 8592466
    Abstract: Treatment of humans suffering from conditions caused by higher-than-normal dopaminergic activity in basal ganglia includes administering the compound (2S)-2-{3-[3-({[(2R,4R)-4-tert-Butoxycarbonyl-2-(2-fluorophenyl)]-3-thiazolidinyl}carbonylmethyl)ureido]phenyl}propionic acid and its physiological acceptable salts.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: November 26, 2013
    Assignee: Neuropill, Inc.
    Inventor: Ahmed Elkashef
  • Methods for Treating Conditions Caused by Higher-Than-Normal Dopaminergic Activity In Basal Ganglia
    Publication number: 20120289556
    Abstract: Treatment of humans suffering from conditions caused by higher-than-normal dopaminergic activity in basal ganglia includes administering the compound (2S)-2-{3-[3-({[(2R,4R)-4-tert-Butoxycarbonyl-2-(2-fluorophenyl)]-3-thiazolidinyl}carbonylmethyl)ureido]phenyl}propionic acid and its physiological acceptable salts.
    Type: Application
    Filed: July 18, 2012
    Publication date: November 15, 2012
    Applicant: Neuropill, Inc.
    Inventor: Ahmed ELKASHEF
  • Methods for treating schizophrenia
    Patent number: 8247438
    Abstract: Treatment of schizophrenia or humans suffering from conditions associated with high dopamine levels in ventral striatum or caudate nucleus administers the compound (2S)-2-{3-[3-({[(2R,4R)-4-tert-Butoxycarbonyl-2-(2-fluorophenyl)]-3-thiazolidinyl}carbonylmethyl)ureido]phenyl}propionic acid and its physiological acceptable salts.
    Type: Grant
    Filed: June 10, 2008
    Date of Patent: August 21, 2012
    Assignee: Neuropill, Inc.
    Inventor: Ahmed Elkashef
  • METHODS FOR TREATING SCHIZOPHRENIA
    Publication number: 20090215840
    Abstract: Treatment of schizophrenia or humans suffering from conditions associated with high dopamine levels in ventral striatum or caudate nucleus administers the compound (2S)-2-{3-[3-({[(2R,4R)-4-tert-Butoxycarbonyl-2-(2-fluorophenyl)]-3-thiazolidinyl}carbonylmethyl) ureido]phenyl} propionic acid and its physiological acceptable salts.
    Type: Application
    Filed: June 10, 2008
    Publication date: August 27, 2009
    Applicant: Neuropill, Inc
    Inventor: Ahmed Elkashef